FDA Reviews Application to Broaden RSV Preventative Use for Young Children

The FDA has accepted Merck's application to expand the use of ENFLONSIA (clesrovimab-cfor), an RSV preventative treatment. If approved, this monoclonal antibody could be administered to high-risk children under two years old during their second RSV season. This potential expansion offers enhanced protection for vulnerable pediatric populations.